Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Other Non-Current Liabilities (2022 - 2026)

Unicycive Therapeutics filings provide 3 years of Other Non-Current Liabilities readings, the most recent being $18.9 million for Q4 2024.

  • On a quarterly basis, Other Non-Current Liabilities rose 44.18% to $18.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $18.9 million, a 44.18% increase, with the full-year FY2024 number at $18.9 million, up 44.18% from a year prior.
  • Other Non-Current Liabilities hit $18.9 million in Q4 2024 for Unicycive Therapeutics, up from $6.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $24.9 million in Q1 2024 to a low of $6.4 million in Q3 2024.
  • Median Other Non-Current Liabilities over the past 3 years was $12.9 million (2023), compared with a mean of $13.3 million.
  • The widest YoY moves for Other Non-Current Liabilities: up 88.86% in 2024, down 44.68% in 2024.
  • Unicycive Therapeutics' Other Non-Current Liabilities stood at $10.4 million in 2022, then increased by 26.59% to $13.1 million in 2023, then soared by 44.18% to $18.9 million in 2024.
  • The last three reported values for Other Non-Current Liabilities were $18.9 million (Q4 2024), $6.4 million (Q3 2024), and $8.1 million (Q2 2024) per Business Quant data.